S. Deleu

Single‐ and multiple‐dose pharmacokinetics and safety of pimodivir, a novel, non‐nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open‐label study in healthy volunteers

K. Spittaels, J. Vercauteren, T. Kakuda, 2018, British journal of clinical pharmacology.

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

M. Ison, B. O'Neil, A. Torres, 2020, The Journal of infectious diseases.

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long‐acting formulation in healthy volunteers

H. Crauwels, P. Meyvisch, R. Verloes, 2015, HIV medicine.

CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus

M. Gamil, D. Huntjens, T. Toh, 2024, Paediatric drugs.